Atharva BioSciences - leaders in innovative Molecular Diagnostics

Our Lab is for you   

Diagnostic Testing Infectious Diseases
  Overview of Virus About the Assay Collection & Shipping Abstracts & Publications


Miller LE. The Lab and Epstein-Barr Virus Infections. ADVANCE for Medical Laboratory Professionals. 2002:19-21.
Dr. Miller presents a review of the role of laboratory testing in the diagnosis and monitoring of EBV infections.

Rose C, Green M, Webber S, Ellis D, Reyes J et al. Pediatric Solid-Organ Transplant Recipients Carry Chronic Loads of Epstein-Barr Virus Exclusively in the Immunoglobulin D-Negative B-Cell Compartment. Journal of Clinical Microbiology. 2001;39:1407-1415.

Solid-organ transplant recipients are at risk for development of lymphoproliferative diseases. The purpose of this study was to examine the distribution of Epstein-Barr virus (EBV) load in the peripheral blood of pediatric patients who had become chronic viral load carriers (>8 copies/105 lymphocytes for >2 months.) A total of 19 patients with viral loads ranging from 20 to 5,000 viral genome copies/105 lymphocytes were studied. Ten patients had no previous diagnosis of posttransplant lymphoproliferative disease (PT-LPD), while nine had recovered from a diagnosed case of PT-LPD. No portion of the peripheral blood viral load was detected in the cell-free plasma fraction. Viral DNA was found in a population of cells characterized as CD19hi and immunoglobulin D negative, a phenotype that is consistent with the virus being carried exclusively in the memory B-cell compartment of the peripheral blood. There was no difference in the compartmentalization based upon either the level of the viral load or the past diagnosis of an episode of PT-LPD. These results have implications for the design of tests to detect EBV infection and for the interpretation and use of positive EBV PCR assays in the management of transplant recipients.


van Esser JWJ, van der Holt B, Meijer E, Niesters HGM, Trenschel R et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogenic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell depleted SCT. Blood. 2001;98:972-978.

Reactivation of the Epstein-Barr virus (EBV) after allogeneic stem cell transplantation (allo-SCT) may evoke a protective cellular immune response or may be complicated by the development of EBV-lymphoproliferative disease (EBV-LPD). So far, very little is known about the incidence, recurrence, and sequelae of EBV reactivation following allo-SCT. EBV reactivation was retrospectively monitored in 85 EBV-seropositive recipients of a T-cell—depleted (TCD) allo-SCT and 65 EBV-seropositive recipients of an unmanipulated allo-SCT. Viral reactivation (more than 50 EBV genome equivalents ([gEq]/mL) was monitored frequently by quantitative Real Time plasma polymerase chain reaction until day 180 after SCT. Probabilities of developing viral reactivation were high after both unmanipulated and TCD-allogeneic SCT (31% + 6% versus 65% + 7%, respectively). A high CD34+ cell number of the graft appeared as a novel significant predictor (P=.001) for EBV reactivation. Recurrent reactivation was observed more frequently in recipients of a TCD graft, and EBV-LPD occurred only after TCD-SCT. High-risk status, TCD, and use of antihymocyte globulin were predictive for developing EBV-PLD. Plasma EBV DNA quantitatively predicted EBV-LPD. The positive and negative predictive values of a viral load of 1000 gEq/mL were, respectively, 39% and 100% after TCD. Treatment-related mortality did not differ significantly between TCD and non-TCD transplants, but the incidence of chronic graft-versus-host disease was significantly less in TCD patients. It is concluded that EBV reactivation occurs frequently after TCD and unmanipulated allo-SCT, especially in recipients of grafts with high CD34+ cell counts. EBV-LPD, however, occurred only after TCD, and EBV load quantitatively predicted EBV-LPD in recipients of a TCD graft.

Schooley RT. Epstein-Barr Virus (Infectious Mononucleosis). In Mandell GL, Bennett JE, Dolin, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 4th edition, Vol. 2. New York, NY: Churchill Livingstone; 1995:1364-1377.

This chapter appears in the 2nd volume of the definite textbook on infectious diseases. Chapter 118 discusses the history, description, epidemiology, pathogenesis, clinical manifestations, laboratory diagnosis treatment and prevention of Epstein-Barr virus.


Atharva BioSciences
ISO 9001:2000 Certified
B-4/233, Safdarjung Enclave, New Delhi 110 029  Telephone: (+91-11) 6546 7029   Fax: (+91-11) 4135 4257 
email: contact@atharvasciences.com
© Copyright 2008. All Rights Reserved.